Xencor (XNCR) Stock Forecast, Price & News

Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor or view top-rated stocks.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Xencor.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating the consensus estimate of ($0.70) by $1.09. The biopharmaceutical company earned $85.50 million during the quarter, compared to the consensus estimate of $26.17 million. Xencor had a trailing twelve-month return on equity of 15.74% and a net margin of 33.28%. The firm's quarterly revenue was up 152.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) EPS.
View Xencor's earnings history.

What price target have analysts set for XNCR?

8 brokerages have issued 12 month price objectives for Xencor's stock. Their forecasts range from $42.00 to $60.00. On average, they anticipate Xencor's stock price to reach $52.33 in the next year. This suggests a possible upside of 134.0% from the stock's current price.
View analysts' price targets for Xencor or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?

Xencor's management team includes the following people:

• Bassil I. Dahiyat, President, Chief Executive Officer & Director (LinkedIn Profile)
• John J. Kuch, Chief Financial Officer & Senior Vice President
• John R. Desjarlais, Chief Scientific Officer & Senior VP-Research
• Allen Yang, Chief Medical Officer & Senior Vice President
• Celia Eckert, Secretary, General Counsel & Vice President

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Who are some of Xencor's key competitors?

Some companies that are related to Xencor include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Acerus Pharmaceuticals (ASPCF), Alkermes (ALKS), Evotec (EVTCY), Apellis Pharmaceuticals (APLS), Cerevel Therapeutics (CERE), Galapagos (GLPG), Bausch Health Companies (BHC), CureVac (CVAC), Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Mirati Therapeutics (MRTX) and Ultragenyx Pharmaceutical (RARE).
View all of XNCR's competitors.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.76%), Vanguard Group Inc. (10.74%), Primecap Management Co. CA (8.30%), State Street Corp (4.99%), Loomis Sayles & Co. L P (3.05%) and Dimensional Fund Advisors LP (1.56%). Company insiders that own Xencor stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch.
View institutional ownership trends for Xencor.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Federated Hermes Inc., South Dakota Investment Council, Primecap Management Co. CA, Citigroup Inc., Bank of New York Mellon Corp, TD Asset Management Inc., and Strs Ohio. Company insiders that have sold Xencor company stock in the last year include Allen Yang, Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor or view top insider-selling stocks.

Which institutional investors are buying Xencor stock?

XNCR stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Invesco Ltd., Assenagon Asset Management S.A., Loomis Sayles & Co. L P, Tekla Capital Management LLC, Dimensional Fund Advisors LP, and Granahan Investment Management LLC.
View insider buying and selling activity for Xencor or or view top insider-buying stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $22.36.

How much money does Xencor make?

Xencor has a market capitalization of $1.33 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $1.779990 on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 254 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350.